Comparative usability study for a certolizumab pegol autoinjection device in patients with rheumatoid arthritis

Expert Opin Drug Deliv. 2017 Jan;14(1):15-22. doi: 10.1080/17425247.2016.1256283. Epub 2016 Nov 18.


Objectives: To compare the usability of a new certolizumab pegol (CZP) autoinjector with the adalimumab, etanercept, and golimumab devices in patients with rheumatoid arthritis.

Methods: Two identical studies were performed in 2013 and 2016; patients performed a simulated self-injection with the CZP autoinjector and the most up-to-date device versions at the time in a randomized, consecutive sequence. The primary end point was the ranking of the four autoinjectors in order of preference. Device usability and intuitiveness were assessed across a range of secondary and exploratory end points.

Results: The 2013 and 2016 study populations included 76 patients each; a significant majority (2013: 67%; 2016: 59%) ranked the CZP autoinjector as their most preferred device (p < 0.001). Most patients agreed that the CZP autoinjector was easier to use, start, and manipulate, and were more willing to use it than the comparator devices (p < 0.001 for all pairwise comparisons with CZP). Likert score differences also favored the CZP autoinjector regarding how easy it was to determine injection completion. The CZP autoinjector was associated with a low rate of use error.

Conclusions: In both studies, the CZP autoinjector was the preferred choice compared to the alternative devices and was associated with a high level of patient satisfaction.

Keywords: Autoinjector; certolizumab pegol; patient preference; rheumatoid arthritis; usability.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antirheumatic Agents / administration & dosage*
  • Arthritis, Rheumatoid / drug therapy*
  • Certolizumab Pegol / administration & dosage*
  • Female
  • Humans
  • Injections
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Treatment Outcome


  • Antirheumatic Agents
  • Certolizumab Pegol